神经丝轻链在帕金森病诊断与鉴别诊断中的研究进展  

Research progression of neurofilament light chain in the diagnosis and differential diagnosis of Parkinson's disease

作　　者：尹蔚芳 任惠[1] 杨兴隆 YIN Wei-fang;REN Hui;YANG Xing-long(Department of Geriatric Neurology,First Affiliated Hospital of Kunming Medical University,Kunming 650032,Yunnan,China)

机构地区：[1]昆明医科大学第一附属医院老年神经内科,650032

出　　处：《中国现代神经疾病杂志》2022年第4期224-228,共5页Chinese Journal of Contemporary Neurology and Neurosurgery

基　　金：国家自然科学基金地区基金资助项目(项目编号:81960242);广东省医学会岭南神经病学中青年医生临床研究专项支持项目;成都医学院⁃成都市第七人民医院联合科研基金重点项目(项目编号:2020LHJYZD-02);2021年昆明医科大学研究生创新基金资助项目(项目编号:2021S184)。

摘　　要：帕金森病是常见的神经系统变性疾病,疾病负担逐渐加重。神经丝轻链(NfL)作为一种高表达于大口径有髓鞘轴突的神经元胞质蛋白,可作为神经轴突损伤的标志物,是最有前景的帕金森病临床诊断与鉴别诊断的生物学标志物之一,对预测帕金森病严重程度和疾病进展、合并认知功能障碍亦具有重要作用,此外NfL联合影像学标志物亦具有较高的预测价值。本文综述脑脊液和血液NfL在帕金森病中的应用进展,以期对临床实践及后续研究提供帮助。Parkinson's disease(PD)is a common neurodegenerative disease and the disease burden is increasing.Neurofilament light chain(NfL)is a neuronal cytoplasmic protein highly expressed in large calibre myelinated axons which may serve as a biomarker for axonal damage.NfL is one of the most promising biomarkers to be used in clinical diagnosis and differential diagnosis of PD and it also plays an important role in predicting the severity and progression of PD and associated cognitive disorders.Besides,NfL combined imaging biomarkers also has high predictive value.This review provides an overview of the progress achieved thus far exploring the assicaiton between NfL in cerebrospinal fluid or blood,with a view to be providing help for clinical practice and follow⁃up studies.

关 键 词：帕金森病 神经丝蛋白 生物标记 综述 

分 类 号：R742.5[医药卫生—神经病学与精神病学]